Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

Must Read

List of United Bank for Africa (UBA) Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

How To Block Your Bank Account And SIM Card In Case Of Emergency

Losing your phone and wallet or having them stolen can be very frustrating. However, in case that happens to...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...
- Advertisement -

HONG KONG SAR – Media OutReach – 22 February 2021 – This announcement is made by Ocumension Therapeutics (the “Company“, together with its subsidiaries, the “Group“) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

 

The board of directors of the Company (the “Board“) is pleased to announce that an investigational new drug (“IND“) approval for initiating a multi-regional phase III clinical trial (the “Phase III MRCT“) in the United States for OT-101, a self developed product of the Group, has been received from the United States Food and Drug Administration in February 2021. The Company plans to file IND applications with the regulatory authorities in both China and Europe Union in 2021 and initiate the Phase III MRCT of OT-101 in these regions accordingly.

 

- Advertisement -

OT-101 is a low-concentration atropine 0.01% eye drop developed by the Group to retard, or slow down, the progression of myopia in children and adolescents. The instability of low-concentration atropine solutions has long been a technical barrier for its commercialization. The Group developed a storage and delivery system to address low-concentration atropine solution’s instability, and also conducted several rounds of tests on the system’s reliability, closure integrity and sterility conditions.

Read Also:  COVID-19 Prompts Tang Prize Laureates to Examine New Challenges Facing Sustainable Development
Read Also:  Fuji Xerox Asia Pacific Extends Partnership with Esker, Launches Digital Accounts Receivable Solution

 

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-101 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

 

- Advertisement -

By order of the Board of

Ocumension Therapeutics

Dr. Lian Yong CHEN

Chairman and Executive Director

- Advertisement -

 

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

- Advertisement -
Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States - Brand SpurVoluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -
Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States - Brand SpurVoluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States - Brand Spur

Latest News

DLM Group Celebrates IWD With Abike Dabiri And Juliet Ehimuan

DLM Group continues its commitment to celebrate and enable Women leaders on International Women’s Day 2021. In commemoration of...
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States - Brand SpurVoluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States - Brand Spur